{"id":22316,"date":"2024-01-30T08:47:47","date_gmt":"2024-01-30T07:47:47","guid":{"rendered":"https:\/\/ggba.swiss\/?p=22316"},"modified":"2024-01-30T08:51:44","modified_gmt":"2024-01-30T07:51:44","slug":"onward-therapeutics-enters-clinical-phase-with-innovative-cancer-immunotherapy","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/en\/onward-therapeutics-enters-clinical-phase-with-innovative-cancer-immunotherapy\/","title":{"rendered":"Onward Therapeutics enters clinical phase with innovative cancer immunotherapy"},"content":{"rendered":"\n

In February 2021, Onward Therapeutics<\/a> secured exclusive worldwide rights for the development, manufacture, and commercialization of OT-A201 from Biomunex Pharmaceuticals<\/a>. This collaboration involves co-developing the bispecific antibody until the completion of the phase 1 study. OT-A201, a first-in-class humanized bispecific antibody, targets two immune checkpoints, holding immense potential for treating advanced hematological malignancies and solid tumors.<\/p>\n\n\n\n

OT-A201’s preclinical studies have shown promising results, exhibiting excellent specificity, safety, and notable anti-tumoral activities at various doses. This antibody, based on Biomunex’s BiXAb technology, also features a functional Fc domain that contributes to ADCC activity against tumor cells, displaying properties like good pairing, low aggregation, and high stability.<\/p>\n\n\n\n

Advancing innovative projects in the fight against cancer<\/h4>\n\n\n\n

The newly launched European multicenter study, No. A20101, aims to assess the safety, tolerability, pharmacokinetics, and preliminary anti-tumoral efficacy of OT-A201. This open-label study comprises two parts: a dose escalation stage for patients with specific relapsed\/refractory hematological malignancies or advanced\/metastatic solid tumors, and an expansion stage to further evaluate the antibody’s safety and efficacy as monotherapy or in combination in defined conditions.<\/p>\n\n\n\n

Dosing the first patient has triggered an undisclosed milestone payment to Biomunex, signifying progress in Onward Therapeutics’ journey. Dr. C. Grace Yeh, Chairman and CEO of Onward Therapeutics, expressed enthusiasm about testing OT-A201 in patients, highlighting the company’s efficiency in moving from cell line development to large-scale manufacture and preclinical studies. Yeh’s statement underscores the company’s commitment to its ‘buy-to-build’ business model and marks a crucial milestone in transitioning Onward Therapeutics into a clinical-stage company.<\/p>\n","protected":false},"excerpt":{"rendered":"

Based at the Biop\u00f4le in Lausanne, Onward Therapeutics has made a significant leap in the field of biotechnology by initiating the phase 1 clinical trial of OT-A201, its pioneering bispecific antibody. <\/p>\n","protected":false},"author":6,"featured_media":22317,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[833],"tags":[912,883,902,901],"class_list":["post-22316","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-life-science","tag-biotech","tag-oncology","tag-personalized-medicine","tag-technology-park"],"acf":[],"yoast_head":"\nOnward Therapeutics' cancer immunotherapy enters clinical phase<\/title>\n<meta name=\"description\" content=\"Based at the Biop\u00f4le in Lausanne, Onward Therapeutics has initiated the phase 1 clinical trial of OT-A201, its pioneering antibody.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/en\/onward-therapeutics-enters-clinical-phase-with-innovative-cancer-immunotherapy\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Onward Therapeutics' cancer immunotherapy enters clinical phase\" \/>\n<meta property=\"og:description\" content=\"Based at the Biop\u00f4le in Lausanne, Onward Therapeutics has initiated the phase 1 clinical trial of OT-A201, its pioneering antibody.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/en\/onward-therapeutics-enters-clinical-phase-with-innovative-cancer-immunotherapy\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2024-01-30T07:47:47+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-01-30T07:51:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ggba.swiss\/app\/uploads\/2024\/01\/Onward-Therapeutics-Cancer-Treatment-1024x704.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"704\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Pierre-Yves Oehrli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pierre-Yves Oehrli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/en\/onward-therapeutics-enters-clinical-phase-with-innovative-cancer-immunotherapy\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/en\/onward-therapeutics-enters-clinical-phase-with-innovative-cancer-immunotherapy\/\"},\"author\":{\"name\":\"Pierre-Yves Oehrli\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"headline\":\"Onward Therapeutics enters clinical phase with innovative cancer immunotherapy\",\"datePublished\":\"2024-01-30T07:47:47+00:00\",\"dateModified\":\"2024-01-30T07:51:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/en\/onward-therapeutics-enters-clinical-phase-with-innovative-cancer-immunotherapy\/\"},\"wordCount\":265,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/en\/onward-therapeutics-enters-clinical-phase-with-innovative-cancer-immunotherapy\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/01\/Onward-Therapeutics-Cancer-Treatment.jpeg\",\"keywords\":[\"Biotech\",\"Oncology\",\"Personalized Medicine\",\"Technology Park\"],\"articleSection\":[\"Life sciences\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ggba.swiss\/en\/onward-therapeutics-enters-clinical-phase-with-innovative-cancer-immunotherapy\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/en\/onward-therapeutics-enters-clinical-phase-with-innovative-cancer-immunotherapy\/\",\"url\":\"https:\/\/ggba.swiss\/en\/onward-therapeutics-enters-clinical-phase-with-innovative-cancer-immunotherapy\/\",\"name\":\"Onward Therapeutics' cancer immunotherapy enters clinical phase\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/en\/onward-therapeutics-enters-clinical-phase-with-innovative-cancer-immunotherapy\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/en\/onward-therapeutics-enters-clinical-phase-with-innovative-cancer-immunotherapy\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/01\/Onward-Therapeutics-Cancer-Treatment.jpeg\",\"datePublished\":\"2024-01-30T07:47:47+00:00\",\"dateModified\":\"2024-01-30T07:51:44+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"description\":\"Based at the Biop\u00f4le in Lausanne, Onward Therapeutics has initiated the phase 1 clinical trial of OT-A201, its pioneering antibody.\",\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/en\/onward-therapeutics-enters-clinical-phase-with-innovative-cancer-immunotherapy\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/en\/onward-therapeutics-enters-clinical-phase-with-innovative-cancer-immunotherapy\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ggba.swiss\/en\/onward-therapeutics-enters-clinical-phase-with-innovative-cancer-immunotherapy\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/01\/Onward-Therapeutics-Cancer-Treatment.jpeg\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/01\/Onward-Therapeutics-Cancer-Treatment.jpeg\",\"width\":2360,\"height\":1622,\"caption\":\"Onward Therapeutics\u2019 move marks a critical transition for the company into the clinical stage, solidifying its role in developing innovative cancer treatments.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/en\/onward-therapeutics-enters-clinical-phase-with-innovative-cancer-immunotherapy\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Onward Therapeutics enters clinical phase with innovative cancer immunotherapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\",\"name\":\"Pierre-Yves Oehrli\",\"url\":\"https:\/\/ggba.swiss\/en\/author\/pierre-yves-oehrli\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Onward Therapeutics' cancer immunotherapy enters clinical phase","description":"Based at the Biop\u00f4le in Lausanne, Onward Therapeutics has initiated the phase 1 clinical trial of OT-A201, its pioneering antibody.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/en\/onward-therapeutics-enters-clinical-phase-with-innovative-cancer-immunotherapy\/","og_locale":"en_US","og_type":"article","og_title":"Onward Therapeutics' cancer immunotherapy enters clinical phase","og_description":"Based at the Biop\u00f4le in Lausanne, Onward Therapeutics has initiated the phase 1 clinical trial of OT-A201, its pioneering antibody.","og_url":"https:\/\/ggba.swiss\/en\/onward-therapeutics-enters-clinical-phase-with-innovative-cancer-immunotherapy\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2024-01-30T07:47:47+00:00","article_modified_time":"2024-01-30T07:51:44+00:00","og_image":[{"width":1024,"height":704,"url":"https:\/\/ggba.swiss\/app\/uploads\/2024\/01\/Onward-Therapeutics-Cancer-Treatment-1024x704.jpeg","type":"image\/jpeg"}],"author":"Pierre-Yves Oehrli","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Pierre-Yves Oehrli","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/en\/onward-therapeutics-enters-clinical-phase-with-innovative-cancer-immunotherapy\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/en\/onward-therapeutics-enters-clinical-phase-with-innovative-cancer-immunotherapy\/"},"author":{"name":"Pierre-Yves Oehrli","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"headline":"Onward Therapeutics enters clinical phase with innovative cancer immunotherapy","datePublished":"2024-01-30T07:47:47+00:00","dateModified":"2024-01-30T07:51:44+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/en\/onward-therapeutics-enters-clinical-phase-with-innovative-cancer-immunotherapy\/"},"wordCount":265,"commentCount":0,"image":{"@id":"https:\/\/ggba.swiss\/en\/onward-therapeutics-enters-clinical-phase-with-innovative-cancer-immunotherapy\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2024\/01\/Onward-Therapeutics-Cancer-Treatment.jpeg","keywords":["Biotech","Oncology","Personalized Medicine","Technology Park"],"articleSection":["Life sciences"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ggba.swiss\/en\/onward-therapeutics-enters-clinical-phase-with-innovative-cancer-immunotherapy\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/en\/onward-therapeutics-enters-clinical-phase-with-innovative-cancer-immunotherapy\/","url":"https:\/\/ggba.swiss\/en\/onward-therapeutics-enters-clinical-phase-with-innovative-cancer-immunotherapy\/","name":"Onward Therapeutics' cancer immunotherapy enters clinical phase","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/en\/onward-therapeutics-enters-clinical-phase-with-innovative-cancer-immunotherapy\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/en\/onward-therapeutics-enters-clinical-phase-with-innovative-cancer-immunotherapy\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2024\/01\/Onward-Therapeutics-Cancer-Treatment.jpeg","datePublished":"2024-01-30T07:47:47+00:00","dateModified":"2024-01-30T07:51:44+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"description":"Based at the Biop\u00f4le in Lausanne, Onward Therapeutics has initiated the phase 1 clinical trial of OT-A201, its pioneering antibody.","breadcrumb":{"@id":"https:\/\/ggba.swiss\/en\/onward-therapeutics-enters-clinical-phase-with-innovative-cancer-immunotherapy\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/en\/onward-therapeutics-enters-clinical-phase-with-innovative-cancer-immunotherapy\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ggba.swiss\/en\/onward-therapeutics-enters-clinical-phase-with-innovative-cancer-immunotherapy\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2024\/01\/Onward-Therapeutics-Cancer-Treatment.jpeg","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2024\/01\/Onward-Therapeutics-Cancer-Treatment.jpeg","width":2360,"height":1622,"caption":"Onward Therapeutics\u2019 move marks a critical transition for the company into the clinical stage, solidifying its role in developing innovative cancer treatments."},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/en\/onward-therapeutics-enters-clinical-phase-with-innovative-cancer-immunotherapy\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/en\/"},{"@type":"ListItem","position":2,"name":"Onward Therapeutics enters clinical phase with innovative cancer immunotherapy"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41","name":"Pierre-Yves Oehrli","url":"https:\/\/ggba.swiss\/en\/author\/pierre-yves-oehrli\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/22316","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/comments?post=22316"}],"version-history":[{"count":1,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/22316\/revisions"}],"predecessor-version":[{"id":22320,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/22316\/revisions\/22320"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/media\/22317"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/media?parent=22316"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/categories?post=22316"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/tags?post=22316"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}